This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simha, V. Articles by Garg, A. Search for Related Content PubMed PubMed Citation Articles by Simha, V. Articles by Garg, A.

Effect of Subcutaneous Leptin Replacement Therapy on Bone Metabolism in Patients with Generalized Lipodystrophy

Division of Nutrition and Metabolic Diseases, Center for Human Nutrition (V.S., A.G.), and Division of Mineral Metabolism (J.E.Z., K.S.), Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390

Address all correspondence and requests for reprints to: Abhimanyu Garg, M.D., Division of Nutrition and Metabolic Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Y3-222, Dallas, Texas 75390-9052. E-mail: abhimanyu.garg{at}utsouthwestern.edu.

Abstract

The adipocyte-derived hormone leptin, which plays an important role in energy homeostasis, has been suggested to have an influence on bone development and remodeling. However, it is not clear from animal studies whether leptin is a stimulator or an inhibitor of bone growth. Cross-sectional studies in humans suggest that serum leptin levels are positively associated with bone mineral density (BMD), but these observations are not consistent, and whether this relationship is independent of obesity remains unclear. We therefore examined the effect of sc leptin administration on BMD and markers of bone turnover in two women, one with congenital generalized lipodystrophy and the other with acquired generalized lipodystrophy. Both patients had regular menstrual cycles. At baseline, the BMD for both patients, measured at the lumbar spine and total hip, was within 1 SD of the peak bone mass. There was no significant change in BMD in both patients after 16–18 months of leptin therapy. Similarly, concentrations of serum osteocalcin and bone-specific alkaline phosphatase or urinary excretion of deoxypyridinoline and N-telopeptides remained unchanged after 6–8 months of leptin therapy, suggesting no effects of leptin on osteoblastic or osteoclastic activity. Our preliminary data suggest that sc leptin replacement in hypoleptinemic patients with generalized lipodystrophy has no effect on the mature adult skeleton.

This article has been cited by other articles:

				K Rousseau, Z Atcha, J Denton, F R A Cagampang, A R Ennos, A J Freemont, and A S I Loudon Skeletal bone morphology is resistant to the high amplitude seasonal leptin cycle in the Siberian hamster J. Endocrinol., September 1, 2005; 186(3): 475 - 479. [Abstract] [Full Text] [PDF]

				C. K. Welt, J. L. Chan, J. Bullen, R. Murphy, P. Smith, A. M. DePaoli, A. Karalis, and C. S. Mantzoros Recombinant Human Leptin in Women with Hypothalamic Amenorrhea N. Engl. J. Med., September 2, 2004; 351(10): 987 - 997. [Abstract] [Full Text] [PDF]

				E. D. Javor, S. A. Moran, J. R. Young, E. K. Cochran, A. M. DePaoli, E. A. Oral, M. A. Turman, P. R. Blackett, D. B. Savage, S. O'Rahilly, et al. Proteinuric Nephropathy in Acquired and Congenital Generalized Lipodystrophy: Baseline Characteristics and Course during Recombinant Leptin Therapy J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3199 - 3207. [Abstract] [Full Text] [PDF]